Ibrutinib: a promising novel therapy for B-cell hematologic malignancies
Discoveries Reports · 2014
DOI: 10.15190/drep.2014.3 ↗At a glance
Journal article in Discoveries Reports, 2014. Written by Georgiana Roxana Dumitrascu and 1 co-authors.
Abstract (original language)
B cell malignancies are hematological disorders that originate from either precursors or mature B cells. Uncontrolled proliferation of B lymphocytes occurs in both non-Hodgkin lymphoma and Hodgkin lymphoma. Non-Hodgkin lymphoma is one of the most common types of cancer in United States, in contrast to Hodgkin lymphoma, and 85 % of non-Hodgkin lymphoma originates from proliferation of B lymphocytes. It is well known that among high toxicity induced by single or combined therapy, the resistance to treatment and frequent relapsed/refractory disease are also real challenges in the treatment of the complex B-cell non-Hodgkin lymphomas. Thus, new strategies for treatment are urgently needed. Ibrutinib (PCI-32765) is a new therapy for hematological malignancies affecting the mature B-cell. Recently approved by FDA for treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia and also designated by European Medicines Agency as an orphan drug for rare conditions, such as diffuse large B-cell lymphoma and follicular lymphoma, Ibrutinib could be a great strategy for treatment of non-responders to the first-line therapies, with a tremendous potential for elderly patients. Due to the irreversibly covalent binding of Ibrutinib with Bruton’s tyrosine kinase (Btk), a great efficacy and less toxicity were reported for small lymphocytic lymphoma, prolymphocytic leukemia, multiple myeloma, hairy cell leukemia, Waldenstrom's macroglobulinemia and marginal zone lymphoma. New insights in Ibrutinib’s mechanisms of action and resistance to therapy may contribute to the development of novel efficacy strategies for personalized therapy of B-cell malignancies and also to a better control of the severe adverse reaction.
Cite
APA
Dumitrascu, G. R., & Bucur, O. (2014). Ibrutinib: a promising novel therapy for B-cell hematologic malignancies. Discoveries Reports. https://doi.org/10.15190/drep.2014.3
Vancouver
Dumitrascu GR, Bucur O. Ibrutinib: a promising novel therapy for B-cell hematologic malignancies. Discoveries Reports. 2014. doi:10.15190/drep.2014.3
BibTeX
@article{Dumitrascu2014,
author = {Dumitrascu, Georgiana Roxana and Bucur, Octavian},
title = {Ibrutinib: a promising novel therapy for B-cell hematologic malignancies},
journal = {Discoveries Reports},
year = {2014},
doi = {10.15190/drep.2014.3}
}
EUVIMED